Genetically engineered Sertoli cells are able to survive allogeneic transplantation

Area of Science:

• Reproductive Biology
• Immunology
• Biotechnology

Background:

• The testis exhibits immunoprotective properties, enabling Sertoli cells (SCs) to survive allogeneic and xenogeneic transplantation.
• This resilience suggests SCs could be engineered for therapeutic protein delivery.

Purpose of the Study:

• To investigate the survival and sustained protein expression of transplanted Sertoli cells (SCs).
• To evaluate SCs as a potential platform for delivering therapeutic proteins in vivo.

Main Methods:

• SCs isolated from transgenic mice expressing green fluorescent protein (GFP) were transplanted under the kidney capsule of SCID and Balb/c mice.
• Graft survival and GFP expression were assessed using fluorescence microscopy and immunohistochemistry at 30 and 60 days post-transplantation.

Main Results:

• Transplanted SCs survived and continued to express GFP in both SCID and Balb/c recipients for up to 60 days.
• In contrast, islet grafts in Balb/c mice were rejected, highlighting SCs' superior survival in immunocompetent hosts.

Conclusions:

• Sertoli cells demonstrate remarkable survival post-transplantation in both immunodeficient and immunocompetent models.
• Engineered SCs hold promise for in vivo production of therapeutic proteins like insulin, factor VIII, or dopamine.